Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-2 pulsed DC1 vaccine in HER2+ breast cancer
NCT05325632Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2021
- Primary completion
- Feb 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of her-2 pulsed dc1 in HER2-positive breast cancer, sponsored by Moffitt Cancer Center. Started Oct 2021; status: recruiting.
02
Drugs
her-2 pulsed dc1
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05325632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325632.